4,5-二氯-7H-吡咯并[2,3-D]嘧啶 | 115093-90-8

• 物质功能分类: 医药中间体 - 杂环化合物 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并嘧啶类
• 中文名称: 4,5-二氯-7H-吡咯并[2,3-D]嘧啶
• 中文别名: 4,5-二氯-7H-吡咯并2,3-D嘧啶
• 英文名称: 4,5-dichloro-7H-pyrrolo[2,3-d]pyrimidine
• 英文别名: 4,5-dichloro-pyrrolo[2,3-d]pyrimidine
• CAS: 115093-90-8
• 化学式: C₆H₃Cl₂N₃
• mdl: MFCD09999173
• 分子量: 188.016
• InChiKey: VFTPONHUNNOSKG-UHFFFAOYSA-N

物化性质

• 熔点：
  290 °C
• 沸点：
  220.9±50.0 °C(Predicted)
• 密度：
  1.79±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4,5-Dichloro-7h-pyrrolo[2,3-d]pyrimidine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4,5-Dichloro-7h-pyrrolo[2,3-d]pyrimidine
CAS number: 115093-90-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H3Cl2N3
Molecular weight: 188.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4,5-二氯-7H-吡咯并[2,3-D]嘧啶 在 三氯化硼 、 sodium hydride 作用下， 以 二氯甲烷 为溶剂， 反应 1.25h， 生成 4,5-dichloro-7-<(1,3-dihydroxy-2-propoxy)methyl>pyrrolo<2,3-d>pyrimidine
  参考文献：
  名称：

  某些4-取代的和4,5-二取代的7-[（1,3-二羟基-2-丙氧基）甲基]吡咯并[2,3-d]嘧啶的合成，抗增殖和抗病毒活性。

  摘要：

  用[1,3-双（苄氧基）-2-丙氧基]氯甲烷处理4-氯和几个4-氯-5-取代-7H-吡咯并[2,3-d]嘧啶的钠盐（6 ）提供相应的4-氯-和4-氯-5-取代-7-[[[1,3-双（苄氧基）-2-丙氧基]甲基]吡咯并[2,3-d]嘧啶（7-11 ）。在-78℃下用三氯化硼进行脱苄基作用，得到4-氯-和几个4-氯-5-取代的-7-[（（1,3-二羟基-2-丙氧基）甲基]吡咯并[2,3-d]嘧啶（ 12.16）。随后的12-16的胺化得到4-氨基-5-取代的-7-[（（1，3-二羟基-2-丙氧基）甲基]吡咯并[2，3-d]嘧啶（17-21）。用甲胺处理14，用乙胺处理13和14，得到4-（烷基氨基）-5-卤代7-[（1,3-二羟基-2-丙氧基）甲基]吡咯并[2,3-d]嘧啶（22 -24）。在回流的2-丙醇中用羟胺处理12-15，得到5-取代的-4-（羟氨基）-7-[（1,3-二羟基-2-丙氧基）甲基]吡咯或[2

  DOI：

  10.1021/jm00169a028
• 作为产物：
  描述：

  4-氯-5-甲基-7H-吡咯并[2,3-d]嘧啶 在 N-氯代丁二酰亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 8.0h， 以83%的产率得到4,5-二氯-7H-吡咯并[2,3-D]嘧啶
  参考文献：
  名称：

  4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds

  摘要：

  本发明揭示了替代的4-哌啶-1-基-7H-吡咯并[2,3-D]嘧啶化合物，以及包含它们的组合物和它们的使用方法，用于治疗、预防和管理各种疾病和障碍。

  公开号：

  US20060189638A1

文献信息

• Structural optimization elaborates novel potent Akt inhibitors with promising anticancer activity
  作者：Yang Liu、Yanzhen Yin、Zhen Zhang、Carrie J. Li、Hui Zhang、Daoguang Zhang、Changying Jiang、Krystle Nomie、Liang Zhang、Michael L. Wang、Guisen Zhao

  DOI：10.1016/j.ejmech.2017.06.067

  日期：2017.9

  promising therapeutic strategy for aggressive hematologic malignancies. We describe herein an exploration of novel Akt inhibitors for cancer therapy through structural optimization of previously described 4-(piperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine derivatives. Our studies yielded a novel series of pyrrolopyrimidine based phenylpiperidine carboxamides capable of potent inhibition of Akt1. Notably

  针对Akt的靶向已经被证实是一种合理的癌症治疗方法，并且代表了积极的血液学恶性肿瘤的有前途的治疗策略。我们在这里描述了通过对先前描述的4-（哌嗪-1-基）-7 H-吡咯并[2,3- d ]嘧啶衍生物进行结构优化来探索用于癌症治疗的新型Akt抑制剂。我们的研究产生了一系列新的基于吡咯并嘧啶的苯基哌啶羧酰胺，能够有效抑制Akt1。值得注意的是，10h在套细胞淋巴瘤细胞系和原发性患者肿瘤细胞中均表现出强大的抗增殖作用。低微摩尔剂量的10h诱导G 2细胞凋亡和细胞周期停滞/ M期，并显着下调Jeko-1细胞中Akt下游效应子GSK3β和S6的磷酸化。
• [EN] METTL3 MODULATORS<br/>[FR] MODULATEURS DE METTL3
  申请人：ACCENT THERAPEUTICS INC

  公开号：WO2021081211A1

  公开（公告）日：2021-04-29

  Provided are compounds of Formula (I') or (I) below, or pharmaceutically acceptable salts thereof, and methods for their use and production.

  提供的是下面公式（I'）或（I）的化合物，或者是它们的药用可接受盐，以及它们的用途和生产方法。
• [EN] NOVEL COMPOUNDS AS JNK KINASE INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS UTILISABLES EN TANT QU'INHIBITEURS DES JANUS KINASES
  申请人：SCRIPPS RESEARCH INST

  公开号：WO2015084936A1

  公开（公告）日：2015-06-11

  The present invention is directed to modulators, such as inhibitors, of JNK isoform 2 (JNK2) or isoform 3 (JNK3) comprising compounds of formula (I) or formula (II) as described herein. Compounds of the invention can be used for treatment of a medical disorder in a patient wherein modulation of JNK3 is medically indicated, such as when the disorder is Parkinsons disease (PD) Alzheimer's disease (AD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), myocardial infarction (MI), glaucoma, obesity, diabetes, cancer, rheumatoid arthritis, fibrotic disease, pulmonary fibrosis, kidney disease, liver inflammation, Crohns disease, hearing loss, Prader Willi syndrome, or a condition where modification of feeding behavior is medically indicated.

  本发明涉及调控剂，例如JNK同型2（JNK2）或同型3（JNK3）的抑制剂，包括如本文所述的公式（I）或公式（II）的化合物。 发明中的化合物可用于治疗患者中的医疗障碍，其中JNK3的调控在医学上有指示，例如当障碍是帕金森病（PD）、阿尔茨海默病（AD）、亨廷顿病（HD）、肌萎缩侧索硬化（ALS）、多发性硬化症（MS）、心肌梗死（MI）、青光眼、肥胖、糖尿病、癌症、类风湿性关节炎、纤维化疾病、肺纤维化、肾病、肝脏炎症、克罗恩病、听力损失、普拉德-威利综合症，或修改摄食行为在医学上有指示的状况。
• LIMK2 INHIBITORS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE
  申请人：Burgoon Hugh Alfred

  公开号：US20090264450A1

  公开（公告）日：2009-10-22

  Inhibitors of LIM kinase 2 are disclosed, along with pharmaceutical compositions comprising them and methods of their use. Particular compounds are of the formula:

  LIM激酶2的抑制剂已被披露，以及包含它们的药物组合物和它们的使用方法。特定化合物的化学式如下：
• [EN] COMPOUNDS AND METHODS<br/>[FR] COMPOSÉS ET PROCÉDÉS
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2011149827A1

  公开（公告）日：2011-12-01

  Disclosed are compounds having the Formula (I), wherein X, Y, Z, R1, R2 and R3 are as defined herein, and methods of making and using the same.

  揭示了具有化学式（I）的化合物，其中X、Y、Z、R1、R2和R3如本文所定义，并公开了制备和使用这些化合物的方法。